Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

STLN

HoldHot AirFLAG

The Oncology Institute, Inc. · Healthcare · United States · $629M · Avg Vol: $9M/d

63
StockRank
Get insider-trade alerts
Q
46
V
30
M
80
P/E (TTM)
ROE
D/E
Dividend %
AI CONVICTION THESIS

Insufficient evidence for a screen-pass. The Oncology Institute, Inc.: fails the quant gate on quality, value (Q46/V30/M80; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.

COMPANY DESCRIPTION

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue252.5M324.2M393.4M502.7M25.8%587.2M665.0M883.9M32.6%
EPS0.02-0.92-0.71-0.54-0.29-0.16
Shares73.3M74.1M75.7M98.9M+34.9%101.9M
Debt108.2M119.7M123.2M103.7M-1.4%104.8M
Equity123.2M57.0M3.6M-15.7M-82.9%
Op CF-61.8M-36.3M-26.5M-24.6M
Inv CF-131.6M62.6M46.2M-3.1M
Fin CF92.2M-6.8M-3.5M11.6M
Loading 1Y...
PRICE (1Y)+29.8%
4.995.415.826.246.66Aug 5Aug 26Sep 16
SMA 50SMA 200

Close
$6.53
RSI (14)
49.3
52W High
$7.05
From 52W High
0.9%

SCORE BREAKDOWN

Quality
46
ROIC
-30.6%24.3
ROE
N/A
GP/Assets
56.0%89.6
Op. Margin
-2.9%31.0
FCF/Assets
5.2%71.1
Piotroski
549.1
Int. Cover
-3.8x28.4
D/E Ratio
N/A
Current Ratio
1.36x22.1
Value
30
P/E (TTM)
N/A
EV/EBITDA
-34.6x25.0
P/FCF
73.1x21.8
P/B
-23.9x25.0
P/S
1.0x83.9
Div Yield
N/A
Momentum
80
52W High %
93%89.5
RS 6M
69%93.4
SMA 50/200
1.39x96.4
EPS Rev 4W
N/A
EPS Rev 12W
N/A
EPS Improve
N/A
Q Growth
N/A

FUNDAMENTALS

Market Cap
$629M
P/E (Forward)
Gross Margin
15.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STLN are excluded.

TickerCompanyMkt CapStockRankSignal
STLNThe Oncology Institute, Inc.(you)$629M63Hold
GMRSGMR Solutions Inc.$681M72Buy
USPHU.S. Physical Therapy, Inc.$1.2B62Hold
PNTGThe Pennant Group, Inc.$1.3B64Hold
INNVInnovAge Holding Corp.$1.5B63Hold
CYHCommunity Health Systems, Inc.$413M73Buy
SRTAStrata Critical Medical, Inc.$528M41Hold
SGRYSurgery Partners, Inc.$1.8B58Hold
ACHCAcadia Healthcare Company, Inc.$2.7B57Hold
OPCHOption Care Health, Inc.$3.6B68Buy

Peer medians: ROE -30.1% · P/E 27.0x · Gross margin 58.3%

The Oncology Institute, Inc. (STLN): Stock Score Summary

The Oncology Institute, Inc. (STLN) has a MoatMap StockRank of 63/100 based on Quality (46/100), Value (30/100), and Momentum (80/100) factor scores. The current signal is HOLD. Insufficient evidence for a screen-pass. The Oncology Institute, Inc.: fails the quant gate on quality, value (Q46/V30/M80; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.

Key Financial Metrics

Price$6.53
Market Cap$629M
Price/Book-23.91
Return on Invested Capital-30.6%
Gross Margin15.7%
Operating Margin-2.9%
Revenue Growth34.6%
Free Cash Flow$9M

The Oncology Institute, Inc. operates in the Medical Care Facilities industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is The Oncology Institute, Inc.’s (STLN) StockRank?
MoatMap’s StockRank for The Oncology Institute, Inc. (STLN) is 63/100, with a Hold signal. It is a composite of Quality (46), Value (30), and Momentum (80) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does The Oncology Institute, Inc. have an economic moat?
The Oncology Institute, Inc. (STLN) has a Quality factor score of 46/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is The Oncology Institute, Inc. a buy, hold, or sell?
MoatMap’s current signal for The Oncology Institute, Inc. (STLN) is Hold, based on a StockRank of 63/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is The Oncology Institute, Inc. in?
The Oncology Institute, Inc. (STLN) operates in the Healthcare sector, specifically the Medical Care Facilities industry (United States).